

- Myocardial infarction (MI) (*Cont.*):
 mitral regurgitation in, 1543
 murmur after, 51e-2, 1600
 natural history of, 1439
 nausea and vomiting in, 259
 non-ST-segment elevation, 1593, 1594, 1595f.
 See also Non-ST-segment elevation
 acute coronary syndrome (NSTEMI-ACS)
 during PCI, 296e-2, 1602t
 postmenopausal hormone therapy and, 2384t
 prevention of, 84, 747
 Q wave abnormalities in, 269e-4f, 269e-5f,
 269e-8f, 1456, 1456f
 radiation-associated, 103e-4, 621
 right ventricular. *See* Right ventricular failure/
 infarction
 ST-segment elevation. *See* ST-segment
 elevation myocardial infarction
 (STEMI)
 systems-based analysis of, 87e-4
 treatment of
 fibrinolytic therapy, 758
 implantable cardiac defibrillator, 1770
 pacemaker, 1475-1476, 1475t
 racial/ethnic disparities in, 16e-2, 16e-3f
 in women, 6e-3, 6e-3f
 Myocardial ischemia. *See also* Ischemic heart
 disease
 anterior wall, 17, 269e-1f, 1455f
 anterolateral wall, 269e-2f
 in aortic stenosis, 1579
 clinical features of, 1439
 diagnosis of, 1440
 dyspnea in, 47e-1t, 47e-3
 ECG in, 269e-1-3f, 1455-1457, 1455f, 1456f,
 1457f, 1580
 effects of, 1579-1580
 lateral, 269e-2f
 with left ventricular hypertrophy, 1579
 pathophysiology of, 1578-1579, 1580f
 silent, 1580, 1592-1593, 1598
 transmural, 17, 1455f
 ventricular tachycardia in, 1496
 Myocardial perfusion imaging
 after myocardial infarction, 270e-20, 270e-20f
 in CAD evaluation, 270e-10, 270e-10f,
 270e-11f, 271e-2f, 271e-3f
 in chest pain evaluation, 271e-3f, 271e-3v
 indications for, 270e-3
 in ischemic heart disease, 1582, 1584f
 multidimensional, 270e-5f
 in myocardial infarction, 1601
 in myocardial infarction evaluation, 271e-5f
 PET vs. SPECT, 270e-3
 protocols for, 270e-3
 radiation exposure from, 270e-8
 radiopharmaceuticals for, 270e-3, 270e-3t
 in wall motion abnormalities, 270e-4f
 Myocarditis, 1557
 bacterial, 1561
 cardiogenic shock in, 1762. *See also*
 Cardiogenic shock
 CMR in, 270e-15, 270e-15f
 in dermatomyositis, 1562
 dilated cardiomyopathy and, 1558t. *See also*
 Dilated cardiomyopathy
 in diphtheria, 979
 eosinophilic, 1562
 fungal, 1561
 giant cell, 1561-1562
 granulomatous, 1561
 in HIV infection, 1560
 hypersensitivity, 1562
 in influenza, 1212
 parasitic, 1560-1561
 pathophysiology of, 372e-24t
 in relapsing fever, 1147
 ricketsial, 1561
 SA node dysfunction in, 1467, 1467t
 in sarcoidosis, 1561, 1562
 spirochetal, 1561
 viral
 acute, 1558, 1762
 chronic, 1558
 clinical features of, 1558
 diagnosis of, 1558-1560, 1559f
 enteroviral, 1282
 pathophysiology of, 1557-1558
 treatment of, 1560
 viruses causing, 1558
 Myocardium
 oxygen supply and demand, 1578-1579
 regenerative potential of, 265e-12
 rupture of, 289e-3, 1762
 Myoclonic epilepsy and ragged red fiber
 syndrome. *See* MERRF
 Myoclonic seizures, 2544
 Myoclonus, 2623
 Baltic, 451e-4t
 clinical features of, 2619t, 2623
 in Creutzfeldt-Jakob disease, 453e-4
 posthypoxic, 1782
 treatment of, 2623
 Myocytes, 265e-5
 Myofascial pain syndrome, 93, 237, 2246
 Myofasciitis, 2199
 Myofibrillar myopathies, 462e-12, 462e-13t
 Myogenic ptosis, 207
 Myogenic reflex, 332e-2, 1800
 Myoglobin, 625, 625t, 1804, 2762t
 Myoglobinuria, 462e-15, 1212
 Myokymia, 462e-3, 2649, 2664
 Myonecrosis
 anaerobic bacterial, 1099
 clostridial. *See* Gas gangrene (clostridial
 myonecrosis)
 etiology of, 828t
 with necrotizing fasciitis, 831
 synergistic nonclostridial anaerobic, 831
 Myopathy(ies)
 acute necrotizing, 619, 1784
 alcoholic, 2725
 clinical features of, 462e-1-4, 462e-2t, 462e-3t
 congenital, 462e-12, 462e-14
 in critical/systemic illness, 462e-19, 1784
 in diabetes mellitus, 462e-19
 diagnosis of, 462e-1f, 462e-2f, 462e-4-5
 distal, 462e-12, 462e-13t
 drug-induced, 462e-19-20, 462e-20t, 2199,
 2218t, 2447-2448
 gait disorders in, 163
 hereditary, 462e-5, 462e-5t. *See also* Muscular
 dystrophy
 in HIV infection, 1266-1267
 inflammatory. *See* Inflammatory myopathies
 in lung cancer, 511
 mitochondrial. *See* Mitochondrial
 myopathy(ies)
 in parathyroid disorders, 462e-19
 in pituitary disorders, 462e-19
 progressive, in type IIIa glycogen storage
 disease, 436e-6f
 thick-filament, 1784
 in thyroid disorders, 462e-18
 weakness in, 155-156, 2197-2199
 Myopericarditis, vaccinia vaccine and, 261e-7
 Myophosphorylase deficiency (McArdle's
 disease; type V GSD), 433e-2t, 433e-4,
 462e-14
 Myopia, 195
 Myosin
 in cardiac contraction, 265e-5, 265e-5f
 defects in, 1556f
 in rheumatic fever, 372e-24t
 Myosin-binding protein C gene, 437
 Myosin light chain, 265e-4
 Myositis
 clinical features of, 831
 etiology of, 828t, 831
 inclusion body. *See* Inclusion body myositis
 in influenza, 1212
 necrotizing autoimmune, 2198
 in SLE, 2127
 streptococcal, 831, 968
 treatment of, 832-833
 in trichinellosis, 1410
 Myositis ossificans, 426e-7t, 426e-8
 Myositis ossificans progressiva, 426e-7, 426e-7t
 Myotonia
 channelopathies in, 444e-2t
 in chloride channel disorders, 462e-18
 conditions associated with, 462e-3
 definition of, 462e-3
 diagnosis of, 462e-4, 462e-4t
 in muscular dystrophy, 462e-10
 potassium-aggravated, 462e-18
 Myotonia congenita, 444e-2t
 Myotonic discharges, EMG, 442e-4
 Myotonic dystrophy, 462e-9
 AV conduction block in, 1471, 1471t
 clinical features of, 462e-5t, 462e-10
 congenital, 462e-10
 diagnosis of, 462e-10-11
 genetic considerations in, 434, 440t, 462e-5t,
 462e-10-11
 ocular involvement in, 208
 SA node dysfunction in, 1467, 1467t
 testicular dysfunction in, 2366
 treatment of, 462e-11
 Myotubular (centronuclear) myopathy, 462e-12,
 462e-14
 MyPlate Food Guide, 95e-3
 MYPPC3 gene mutations, 1555t, 1568
 Myringoplasty, 230
 Myringotomy, 230
 Mystic sage (*Salvia divinorum*), 469e-4
 Myxedema
 clinical features of, 2291
 edema in, 253
 etiology of, 1651
 hypothermia in, 478e-3
 pericardial effusion in, 1575
 pretibial, 76e-16f, 1654
 Myxedema coma, 2293
 Myxofibrosarcoma, 119e-1
 Myxoma, 289e-1
 clinical features of, 289e-1
 CMR in, 270e-24, 289e-2f
 dyspnea in, 47e-3
 echocardiography in, 289e-1, 289e-1f
 epidemiology of, 289e-1
 heart sounds/murmur in, 51e-6, 289e-1
 vs. mitral stenosis, 1541
 palpitations in, 254
 pathology of, 289e-1
 skin manifestations of, 359
 syncope in. *See* Cardiac syncope
 treatment of, 289e-2
 N
 NAAT (nucleic acid amplification test), 214e-9,
 769t, 1247, 1247t
 Nab-paclitaxel, 103e-12t, 103e-15, 557, 557t
 Nabumetone, 2232
 N-acetyl-benzoquinone-imine (NAPQI), 2027
 N-acetylcysteine (NAC), 43
 for acetaminophen overdose, 2027
 for COPD, 1706
 for idiopathic pulmonary fibrosis, 1712
 for prevention of contrast-induced
 nephropathy, 1461
 for sulfur mustard exposure, 262e-4
 N-acetylprocainamide (NAPA), 35
 Na⁺-Cl⁻ co-transporter, thiazide-sensitive, 296,
 310
 Nadolol
 for arrhythmias, 1480t
 dosage of, 1480t
 for ischemic heart disease, 1589t
 for long QT syndrome, 1497
 overdosage/poisoning with, 473e-9t
 pharmacology of, 1480t
 Naegleria, 1367
 Naegleria infections
 clinical features of, 1367
 encephalitis, 896
 epidemiology of, 245e-4t, 1367
 laboratory evaluation of, 245e-4t, 245e-6t,
 1367
 pathogenesis of, 896, 1367
 treatment of, 246e-11, 1367
 Nafamostat, 310